Abstract: Provided is a technique which, in the design of intraocular lenses, simplifies design work and makes it possible for aberration of the entire eyeball to more precisely match a target value when the designed intraocular lens is inserted into a patient's eye. This intraocular lens design method involves deriving an intraocular lens aberration target value from the aberration of the cornea and anterior chamber and a set value of the total eyeball aberration (S102), and determining an intraocular lens shape such that the at least the aberration of the intraocular lens coincides with the target value (S103-S107). The intraocular lens aberration is set to an intraocular lens aberration for which prescribed convergent light is incident to the intraocular lens (S104).

Abstract: Provided is a technology for suppressing discoloration of a halo-isoquinoline derivative-containing aqueous composition during high-temperature storage. Provided is an aqueous composition containing a compound of formula (1): wherein X is a halogen atom, a salt of the compound, or a solvate of the compound or the salt; and a carbonic anhydrase inhibitor.

Abstract: An intraocular lens insertion tool including: a cylindrical tool body provided with a placement part at which is placed an intraocular lens having an optical part, and a pair of support parts extending from either side of the optical part; and a plunger for pushing out the intraocular lens; the intraocular lens insertion tool being provided in a state in which the intraocular lens is preset in the placement part, wherein at least one of the front support part extending toward a tip end of the tool body and the rear support part extending toward a rear end of the tool body is pre-deformed by abutting against an abutting projection disposed inside the placement part.

Abstract: A supporter includes a small number of members and has a simple fitting method. It can give an intraperitoneal pressure rise effect to a supporter wearer, attain retroflexion suppression, and stabilize the sacroiliac joint. The supporter includes a base material which is formed of a knitted fabric by warp knitting and in which a knitting direction of the knitted fabric is set to be a longitudinal direction. Stretchability in the longitudinal direction is given, while stretchability in a short direction is suppressed. It has a back-supporting section that is a central portion of the base material, projection sections provided by projecting upward both end portions disposed on both sides of the back-supporting section, and curved sections each making the vicinity of the boundary between the back-supporting section and each of the projection sections. Each curved section is curved into a shape of approximate “”.

Abstract: An intraocular lens insertion tool including: a cylindrical tool body provided with a placement part at which is placed an intraocular lens having an optical part, and a pair of support parts extending from either side of the optical part; and a plunger for pushing out the intraocular lens; the intraocular lens insertion tool being provided in a state in which the intraocular lens is preset in the placement part, wherein at least one of the front support part extending toward a tip end of the tool body and the rear support part extending toward a rear end of the tool body is pre-deformed by abutting against an abutting projection disposed inside the placement part.

Abstract: This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemia states, such as hyper-LDL cholesterolemia, in mammals, including humans. This invention pertains to a drug composition for preventing and/or treating dyslipidemia and the like, said drug composition comprising the following: (R)-2-[3-[[N-(benzoxazole-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of either; and an omega-3 fatty acid or an ester derivative of an ?-3 fatty acid.

Abstract: An object of the present invention is to provide a drug that contains a compound for inhibiting neutral lipid accumulation in cardiovascular tissue or cells and has an excellent prophylactic or therapeutic effect on cardiovascular complications of diabetes. The present invention relates to a prophylactic and/or therapeutic agent for cardiovascular complications of diabetes, the agent containing a compound (preferably a medium-chain fatty acid and/or a medium-chain triglyceride) for inhibiting neutral lipid accumulation.

Abstract: An intraocular lens wherein an outer edge of a support part has a curved concave shape at a base thereof and extends therefrom toward a tip thereof with a curved convex shape having a radius of curvature of 5.25 to 7.50 mm. In a region where a Y coordinate of an orthogonal coordinate system is 1.0 mm or greater, an origin of the coordinate system being a geometric center of an optical part, an inner edge of the support part is positioned between shapes obtained by offsetting the outer edge of the support part by 0.2 mm and by 1.0 mm towards the X-axis origin. The tip of the support part is positioned in a region where the Y coordinate is greater than a radius of the optical part, outside a circle with a radius of 5.0 mm centered on the origin.

Abstract: A polymerizable UV-absorbing colorant monomer is provided, which is excellent in stability under alkaline conditions and which is available for a useful material polymer for an intraocular lens. A compound, which is represented by the following general formula (1), is used as a polymerizable UV-absorbing monomer available for a material polymer for an intraocular lens: (in the general formula (1), R1 is a hydrogen atom, a hydroxy group, a carboxy group, an alkyl group having 1 to 8 carbon atoms, an alkoxy group having 1 to 8 carbon atoms, a sulfonic acid group, or a benzyloxy group, R2 is a hydrogen atom, a hydroxy group, or an alkoxy group having 1 to 4 carbon atoms, and R3 is represented by the following formula (2)): (in the general formula (2), R4 is a hydrogen atom or a methyl group, and R5 is a single bond or an alkylene group having 1 to 4 carbon atoms which may have a substituent or substituents.

Abstract: The present invention provides a compound useful in the prevention and treatment of nonalcoholic fatty liver disease. The invention relates to a drug for the prevention and/or treatment of nonalcoholic fatty liver disease, the drug having as an active ingredient (R)-2-[3-[[N-(benzoxazol-2-yl)-N-3-(4-methoxyphenoxy)propyl]aminomethyl]phenoxy]butyric acid, a salt thereof, or a solvate of these.

Abstract: The present invention provides: a compound represented by general formula (I) below, that has both angiotensin II receptor antagonism and a PPAR? activation effect and that is useful as a preventative and/or therapeutic agent for high blood pressure, cardiac disease, arteriosclerosis, type-2 diabetes, and the like; and a drug composition containing the compound. General formula (I) (in the formula: ring A represents a pyridine ring; ring B represents a tetrazole ring or an oxadiazol-5(4H)-one ring; X represents C—R5 or a nitrogen atom; R1 represents an alkyl group; R2 represents an alkyl group or a cycloalkyl group; and R3, R4, and R5 each independently represents a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group or similar.

Abstract: Disclosed herein is an edge-type lighting device which is configured such that when a light guide plate thermally expands, a light source is prevented from being pressed. In the lighting device according to the present invention, a light guide plate (2) is slidably supported so that the light guide plate (2) can expand in the planar direction, and a light source (3) disposed on an edge of the light guide plate (2) is movably supported in the same direction. A light-guide-plate stopper (4b) is disposed at a position facing an edge (2A) of the light guide plate (2) to prevent the light guide plate (2) from expanding excessively. Thus, the light source (3) can be prevented from being pressed toward a frame member (4).

Abstract: A method for preparing optically active 1-bromo-1-[3,5-bis(trifluoromethyl)-phenyl]ethane having a high optical purity, which comprises the step of brominating optically active 1-[3,5-bis(trifluoromethyl)phenyl]ethanol by using, as a brominating agent, (a) a combination of a phosphorus halide and hydrogen bromide, (b) a combination of 1,2-dibromo-1,1,2,2-tetrachloroethane and an organic phosphorous compound represented by the general formula (I): P(R1)(R2)(R3) (in the formula, R1, R2, and R3 independently represent a C6-10 aryl group, a C6-10 aryloxy group, a C1-10 alkyl group, a C1-10 alkoxyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkoxy group), or (c) a combination of N-bromosuccinimide and a dialkyl sulfide.

Abstract: It is an object of the present invention to provide a novel form of (S)-trans-{4-[({2-[({1-[3,5-bis(trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid, which is useful for preventing and/or treating diseases such as dyslipidemia. (S)-trans-{4-[({2-[({1-[3,5-bis(Trifluoromethyl)phenyl]ethyl}{5-[2-(methylsulfonyl)ethoxy]pyrimidin-2-yl}amino)methyl]-4-(trifluoromethyl)phenyl}(ethyl)amino)methyl]cyclohexyl}acetic acid hydrochloride.

Abstract: The present invention is to create a compound that selectively activates glucokinase in the liver, and in particular, to provide an agent for treating and preventing diabetes and impaired glucose tolerance, wherein the agent has a low hypoglycemia risk. A compound represented by the formula (1) as shown below, or a salt thereof, or a solvate of the compound or the salt: wherein, in the following formula (1), ring A represents a thiazolyl group, a pyridyl group, a pyrazyl group, or a pyrazolyl group; L represents —(CO)—, —(CS)—, or —SO2—; and R1 represents a C1-6 alkyl group, a hydroxy C1-6 alkyl group, a C1-6 alkoxy group, an amino group, a C1-6 alkylamino group, a hydroxyamino group, an N—C1-6 alkylcarbamoyl group, or a group represented by the formula (2) as shown below, wherein R3 represents a C1-6 alkyl group; and R2 represents a hydrogen atom, a halogen atom, a C1-6 alkyl group, a C1-6 alkoxy group, or a carboxyl group.

Abstract: A perimeter having means for setting a measurement coordinate system CS, a detector for blind spots, a means for measuring a visual field of the same subject eye based on set measurement coordinate systems at a first and second point of time and a memory for storing the position of the blind spot, a detector for detecting the position of the blind spot at the second point of time and computing amount of deviation with the position of the blind spot, and a control for conducting new measurement coordinate based on the deviation (?).

Abstract: A foot joint supporter includes a first anchor section for tightening the wearer's lower leg with a tubular knitted fabric, a second anchor section for tightening the wearer's instep and sole with the fabric, and a knitted figure eight section between the first anchor section and the second anchor section, being composed of a foot section and a body section and supporting the wearer's talocrural joint. The foot section includes an instep section covering the wearer's instep and a sole section covering the wearer's sole. A stretch resistance, in the length width direction of the tubular knitted fabric, of the sole section is larger than is the stretch resistance, in the length width direction of the tubular knitted fabric, of the instep section.

Abstract: The intraocular lens insertion tool includes a nozzle main body having a nozzle portion 15, a stage portion capable of disposing the intraocular lens 2 in the nozzle main body, and a plunger 60 that presses the intraocular lens 2 set in the stage portion by a leading end, thereby releasing the intraocular lens 2 into an eyeball. The leading end portion 10a of the nozzle portion 15 is obliquely cut so that, as it goes to the front side from the optical axis rear side of intraocular lens 2, the position of the end surface is located on the front side, and at the leading end 61d of the plunger 60, a protruding portion 61e is provided which protrudes to the front side so as to be able to place the surface of the optical axis rear side of the intraocular lens 2.